Phibro Animal Health Raises FY2026 Adj EPS Guidance from $2.93-$3.10 to $2.98-$3.10 vs $3.03 Est; Raises FY2026 Sales Guidance from $1.45B-$1.50B to $1.46B-$1.50B vs $1.488B Est

FISCAL YEAR 2026 FINANCIAL GUIDANCE

Our updated fiscal year 2026 financial guidance is as shown below. Year-over-year percentages are calculated using the midpoint of the guidance ranges.

• Net sales of $1.46 billion to $1.50 billion, 14% growth
• Net income of $92 million to $100 million, 99% growth
• Diluted EPS of $2.25 to $2.44, 97% growth
• Adjusted EBITDA of $247 million to $255 million, 37% growth
• Adjusted net income of $122 million to $127 million, 47% growth
• Adjusted diluted EPS of $2.98 to $3.10, 45% growth
• Adjusted effective tax rate of ~25%

Guidance for GAAP measures assumes no additional foreign exchange (gains) losses for the year ending June 30, 2026 and no recovery of tariffs previously imposed under the International Emergency Economic Powers Act.